ArticleEye (London, England)2023
Relationship between clinical parameters and quality of life in primary Sjögren's Syndrome: a prospective study.
Article in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Comparative efficacy and safety of topical therapies for ocular involvement in Sjögren's syndrome: a systematic review and network meta-analysis.Frontiers in immunology · 2026Pooled it
- Public and Patient Involvement in Research in the Fields of Inflammatory or Autoimmune Ocular Diseases: Protocol for a Scoping Review.JMIR research protocols · 2026Article
- Identifying symptom-based subgroups in Sjögren's disease: a latent class analysis of a patient co-designed survey.BMJ open ophthalmology · 2026Article
- Psychological Aspects of Rheumatic Diseases: Psychorheumatology in Clinical Practice.Rheumatology and therapy · 2026Review
- Health-Related Quality of Life in Primary Sjögren's Syndrome: Oral Manifestations and Patient-Reported Outcomes.Dentistry journal · 2026Article
- Practical Guide to the Local Treatment of Sjogren's Disease.Journal of clinical medicine · 2026Review
- Spotlight on Sjögren's: a patient perspective on burden of illness and unmet needs - results from a real-world survey.RMD open · 2026Article
- Brazilian Registry of Sjögren's Disease (BRAS): a full picture of Sjögren's disease in Brazil.Advances in rheumatology (London, England) · 2025Article
- Calcitonin Gene-Related Peptide Ameliorates Experimental Dry Eye Disease.Investigative ophthalmology & visual science · 2025Article
- Quality of Life and Mental Health Well-Being in Sjögren's Disease in the UK: A Cross-Sectional Comparative Analysis.Journal of clinical medicine · 2025Article
- Time-Dependent Mortality Predictors in Primary Sjögren's Syndrome: C-Reactive Protein for Early Risk and Age for Late Outcomes.Journal of inflammation research · 2025Article
- Association between systemic medication use and severity of dry eye signs and symptoms in the DRy eye assessment and management (DREAM) study.The ocular surface · 2024Article
- Diagnostic Performance of the Tear Meniscus Osmolarity Measurement for Dry Eye Disease in Rheumatoid Arthritis Patients.Diagnostics (Basel, Switzerland) · 2023Article
- The Spectrum of Extraglandular Manifestations in Primary Sjögren's Syndrome.Journal of personalized medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo quantify the impact of dry eye disease (DED) on health and vision related quality of life (HR-QOL, VR-QOL) in patients with Primary Sjögren's Syndrome (pSS).
methodsThirty-four participants with a confirmed diagnosis of pSS as per the 2016 ACR EULAR criteria participated. Main outcome measures included ocular surface parameters and HR-QOL and VR-QOL questionnaires. Clinical examination included visual acuity, Schirmer I testing, ocular surface staining (OSS) and measurement of tear film breakup time. The questionnaires included Ocular Surface Disease Index, National Eye Institute Visual Function Questionnaire-25, Short Form-36 (SF-36) and EULAR Sjogren's Syndrome Patient Reported Index.
resultsDespite the majority of participants (28 female, 6 male, mean age 61.3 years) having attained LogMAR 0.3 or better visual acuity, participants scored low on VR-QOL measures, representing DED related fluctuation in functional vision. All participants suffered from moderate to severe DED. OSS did not correlate with DED symptoms or QOL parameters. Lubricant usage and symptom severity had a statistically moderate to strong negative correlation with VR-QOL and HR-QOL. This was most evident in relation to physical and physiological wellbeing. Compared with normative data, participants had a lower HR-QOL in all scales of the SF-36 ((MD = 9.91 ± 5.16); t(7) = 5.43, p = 0.001).
conclusionsParticipants with pSS have a lower perceived QOL especially in relation to physical and mental wellbeing, correlating to severity of DED symptoms and treatment burden. Clinical signs do not align with symptoms. Therefore, clinicians should remain cognisant, adjusting treatment in accordance with patient reported perceptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.